Log In
BCIQ
Print this Print this
 

ARGX-112

  Manage Alerts
Collapse Summary General Information
Company argenx N.V.
DescriptionHuman mAb targeting interleukin-22 (IL-22) receptor in skin inflammation
Molecular Target Interleukin-22 (IL-22) receptor
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$117.3M

$5.0M

$112.3M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/21/2015

$117.3M

$5.0M

$112.3M

Get a free BioCentury trial today